Avanzini Maria Antonietta, Locatelli Franco, Dos Santos Conceicao, Maccario Rita, Lenta Elisa, Oliveri Mara, Giebel Sebastian, De Stefano Piero, Rossi Francesca, Giorgiani Giovanna, Amendola Giovanni, Telli Stefania, Marconi Massimo
Laboratorio di Immunologia dei Trapianti e Oncoematologia Pediatrica, IRCCS Policlinico San Matteo, Pavia, University of Pavia, Pavia, Italy.
Exp Hematol. 2005 Apr;33(4):480-6. doi: 10.1016/j.exphem.2005.01.005.
Functional recovery of B lymphocytes after hematopoietic stem cell transplantation (HSCT) can take up to 2 years. HSCT recipients may obtain protective titers of pathogen-specific antibody through vaccination, but optimal timing of reimmunization remains to be defined.
In this study, we evaluated the reconstitution of B-cell number and activity in 139 children given HSCT, by B-cell subset phenotyping and in vitro immunoglobulin (Ig) production.
Patients were longitudinally studied at 3, 6, 12, and 18 to 24 months after transplantation. At all time points, recipients displayed a significantly higher percentage of naive (IgD+CD27-) B cells and showed significantly lower production of stimulated in vitro Ig as compared to healthy controls. Moreover, during follow-up, we observed an increase in the proportion of patients who had CD27+ B subsets and who were able to mount in vitro Ig production greater than the 5th percentile.
Similar to what has been described in adults, most children lack memory B cells and produce low amounts of Ig. However, the number of B cells, as well as their function, gradually recovered over time and the spread of data we observed suggests that the reimmunization schedule should be individualized for each patient. It remains to be defined in a prospective clinical study the time point at which a patient should start reimmunization. A reasonable hypothesis to be explored is the time point at which a percentage of memory B cells greater than the 5th percentile of normal controls is reached.
造血干细胞移植(HSCT)后B淋巴细胞的功能恢复可能需要长达2年的时间。HSCT受者可通过接种疫苗获得病原体特异性抗体的保护性滴度,但再次免疫的最佳时机仍有待确定。
在本研究中,我们通过B细胞亚群表型分析和体外免疫球蛋白(Ig)产生情况,评估了139例接受HSCT的儿童的B细胞数量和活性的重建情况。
在移植后3、6、12以及18至24个月对患者进行纵向研究。在所有时间点,与健康对照相比,受者的幼稚(IgD+CD27-)B细胞百分比显著更高,且体外刺激Ig的产生显著更低。此外,在随访期间,我们观察到具有CD27+B亚群且能够在体外产生高于第5百分位数的Ig的患者比例有所增加。
与成人中所描述的情况类似,大多数儿童缺乏记忆B细胞且产生的Ig量较低。然而,B细胞的数量及其功能会随着时间逐渐恢复,我们观察到的数据分布表明,再次免疫计划应针对每位患者进行个体化制定。在一项前瞻性临床研究中确定患者应开始再次免疫的时间点仍有待明确。一个有待探索的合理假设是达到记忆B细胞百分比高于正常对照第5百分位数的时间点。